Loading patent…
AssigneeBoehringer Ingelheim Vetmedical, Inc.
InventorsMichael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
Estimating the term…
The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
A method for reducing the circovirus load in a pig, comprising the step of administering to that pig a single dose of an immunogenic composition containing 4 μg to 400 μg of recombinant PCV2 ORF2 protein per dose and an adjuvant, wherein said adjuvant comprises a polymer of acrylic acid or methacrylic acid, and wherein the circovirus load in a pig is reduced in comparison to a pig not receiving said single dose of the immunogenic composition.
Dependencies are inferred from the claim text.